Zanzalintinib for Neuroendocrine Tumors
(STELLAR-311 Trial)
Trial Summary
What is the purpose of this trial?
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
Research Team
Medical Director
Principal Investigator
Exelixis
Eligibility Criteria
This trial is for people with advanced or widespread neuroendocrine tumors, including pancreatic ones. Participants must have measurable disease, confirmed by tests and scans, and should have seen their cancer grow despite past treatments. They need to provide tumor tissue samples if possible.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either zanzalintinib or everolimus oral tablets once daily
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Everolimus
- Zanzalintinib
Find a Clinic Near You
Who Is Running the Clinical Trial?
Exelixis
Lead Sponsor
Michael M. Morrissey
Exelixis
Chief Executive Officer since 2010
PhD in Chemistry from Harvard University, BSc in Chemistry from the University of Wisconsin
Vicki L. Goodman
Exelixis
Chief Medical Officer since 2022
MD